PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

Multiple sclerosis (MS) is an inflammatory condition that damages the myelin of the central nervous system, leading to neurologic impairment and possibly severe disability. MS is characterized by ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Three investigators and their teams have received funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial Awards. These ...

Research shows that Blacks may develop multiple sclerosis more often than previously thought. Additionally, the symptoms of ...

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...